CLL Microlearning Series – Video #3: Why Zanubrutinib is a Meaningful Option
Why Zanubrutinib is a Meaningful Option
As the CLL treatment landscape continues to evolve, newer BTK inhibitors offer clinicians more refined and tolerable therapy options. In this video, an APP specializing in CLL explains how second-generation BTK inhibitors—particularly zanubrutinib—address limitations seen with first-generation agents like ibrutinib and improve the real-world treatment experience for many patients.
This segment highlights why zanubrutinib has emerged as a meaningful choice in frontline and relapsed CLL, especially for older adults and those with cardiovascular comorbidities who may be more vulnerable to off-target toxicities.
In This Video, You’ll Learn How To:
- How BTK inhibitors have advanced from ibrutinib to more selective, better-tolerated second-generation options
- The key toxicities associated with ibrutinib and how zanubrutinib minimizes off-target effects
- Evidence from the ALPINE trial supporting zanubrutinib’s improved safety and progression-free survival
- Why zanubrutinib may be especially beneficial for patients with pre-existing cardiac conditions or those on anticoagulation